Alkermes has shown more of the data that persuaded it to throw money at its narcolepsy program. The phase 1b readout suggests Alkermes’ ALKS 2680 can hold its own against Takeda’s rival prospect ...

Illumina’s multibillion-dollar quest for Grail—high-reaching, yet ultimately doomed—is nearing its conclusion. The DNA ...

Women have long shouldered the burden of birth control. Now, men may soon have an option that is not only hormone-free, but ...

BridgeBio reported top-line data from the midphase PROPEL 2 trial in March 2023 and followed up with six-month data around one year ago. Tuesday, the biotech unwrapped 12- and 18-month data that add ...

BD is stretching its reach in patient monitoring with the $4.2 billion purchase of Edwards Lifesciences’ connected care ...

Now that’s more like it. After investors frowned on Structure Therapeutics’ oral GLP-1 data in December 2023, the biotech is ...

Arrowhead Pharmaceuticals’ RNA interference (RNAi) therapeutic lowered triglycerides in patients with a rare metabolic ...

As Keytruda’s 2028 patent cliff looms large, Merck & Co.’s renewed R&D oncology strategy focuses on three strategies. | As ...

Rapport Therapeutics is talking up a $122 million IPO, the first in a return to public market interest since an earlier rush ...

Pharmas have a record $1 trillion to deploy on new biotech innovation deals. All they need is for the Federal Reserve to ...

Eli Lilly is splicing another asset onto its neurodegenerative disease pipeline, paying QurAlis $45 million for rights to a ...

The future of hereditary angiodema treatment seems to be coming down to how many shots it takes to reduce attacks. Gene ...